Skip to main content
. 2021 Mar 15;131(6):e143557. doi: 10.1172/JCI143557

Figure 5. Clinical data from patients with breast cancer corroborate the role of fibronectin.

Figure 5

(A) Immunohistochemical staining of small patient cohort for fibronectin in human breast tumors with and without PIK3CA alterations. Tumors with alterations in PIK3CA are shown in blue and those with high fibronectin are shown in red. Unaltered tumors are shown in gray. (B) Representative images of fibronectin IHC in human breast tumors with a PIK3CA (left) alteration and without a PIK3CA alteration (right). Scale bars: 100 μM. (C) Schematic of patient selection and analysis of the METABRIC data set using cBioPortal. (D) Quantification of PIK3CA alterations and alterations in other genes involved in the PI3K pathway, in breast tumors with increased fibronectin as analyzed by cBioPortal using the METABRIC data set.